Group items matching

in title, tags, annotations or url

The Pharmacists' Defence Association (PDA) is playing a vital role in helping pharmacists who are dealing with stress at the workplace. It launched its new awareness factsheet 'It's Time to Address Stress' last week. The factsheet looks at the causes and symptoms of stress in the workplace and provides advice on ways pharmacists can access support and improve working conditions. The association said that it recognises the well-being services offered by employers and specialist charities such as the PDA's charity partner Pharmacist Support play an important part in helping pharmacists who may be experiencing stress. However, the PDA is also committed to working with members to challenge employers to provide well workplaces and to help them to make real impact changes. This can be done by addressing the causes of stress and fulfilling their responsibilities to their employees. It added: "Under the management of Health and Safety at Work Regulations 1999, employers are required by law to protect employees from harm. Their legal obligations include identifying hazards and risks and implementing ways to reduce or eliminate them. The PDA's new factsheet highlights the importance of employers recognising the hazards causing stress as the health and safety issues they are."

The Local Pharmaceutical Committees (LPCs) has rebranded to be known as Community Pharmacy to present a strengthened and unified identity to the local NHS, local government and other stakeholders, as the local voice of community pharmacy. "There are now 58 LPCs in England. The number of LPCs has reduced from 69, with further consolidation expected by April 2024 to a network of 48 local organisations," said Community Pharmacy England. "The changes mean there will be better alignment between LPCs and the 42 NHS Integrated Care Systems in England, who have taken on the responsibility for commissioning pharmaceutical services delegated by NHS England." "This marks a significant milestone, as similar to Community Pharmacy England, LPCs have been undergoing changes to respond to the Review Steering Group (RSG) recommendations on pharmacy representation. The sector voted in favour of the RSG proposals in the summer of 2022, and since then progress has been made on many of the changes at both local and national level as part of the Transforming Pharmacy Representation (TAPR) Programme."

Turning 21 is a significant milestone in a person's life, marking the transition into full-fledged adulthood. It's the age when responsibilities and possibilities both expand, opening the door to a world of new experiences and opportunities. Now that you've reached this exciting age, you're likely wondering what unique and exciting things you can do. Luckily for you, the list is extensive and varied. From exploring the world of wines to finding your own path in the professional world, let's dive into this thrilling journey of discovery together. Whether you're an adventurous spirit or a contemplative soul, there's something here for everyone. So buckle up, as we unfold the multitude of options that await you now that you're 21! Venturing into the World of Wines For many, turning 21 means being able to legally drink alcohol. If you're a wine enthusiast, then you'll be thrilled to know that there are several ways to explore the world of wines. You can take a trip to a local vineyard and sample different varieties or join a wine club for exclusive access to rare bottles and sommelier-led tastings. You can also visit a winery and go on guided tours and pairings to learn more about the production process. No matter which route you choose, you're sure to gain an appreciation for this age-old beverage and its many nuances. Many cities and towns offer wine festivals throughout the year, where you can sample different wines and mingle with fellow enthusiasts. If you're feeling particularly ambitious, you can even take a viticulture class to learn more about how grapes are cultivated and what qualities make up a good bottle of wine.

Advanz Pharma, alongside London-based private equity firms Cinven and HgCapital, is collectively confronted with an £84 million penalty for inflating the price of the thyroid drug by over 1,000 per cent, soaring from £20 to £248 per package over an eight-year period. The Competition Appeal Tribunal endorsed 'all key aspects' of the Competition and Markets Authority's verdict on the companies' culpability in the case, the CMA has said. Advanz stood as the sole supplier of liothyronine tablets, essential for treating thyroid hormone deficiency, with the cost of a packet of these tablets surging over 12-fold between 2009 and 2017. Although Advanz Pharma currently possesses ownership of the company, its former owners, PE firms Cinven and HgCapital, also bear responsibility for the imposed fine, the CMA said. "NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016," Britain's competition watchdog said.

Pharmacy chain Superdrug has introduced what it asserts to be the most affordable private flu vaccinations offered on the UK high street. The vaccinations will be priced at £8.79 for 17.2 million members of its Ghada , and £16.99 for non-members. The 2023-24 vaccination service is set to become available across 150 of its stores starting from early September. Superdrug has taken this step in response to a change in NHS England's inclusion criteria, which has rendered the 12 million individuals aged 50-65 ineligible for the NHS flu vaccination service, the company said. The company is anticipating heightened demand for private flu vaccinations due to the postponed commencement of the NHS service and alterations in eligibility for free flu jabs. "Our waiting list for private flu vaccination services has already exceeded last year's figures, indicating a heightened demand this year," said Ghada Beal, Superdrug's Healthcare Director. "Providing this service at a more accessible price-point is significant, given the eligibility changes that will impact millions. Our private flu vaccination services provide a convenient means for individuals to safeguard themselves against flu and its potential complications." In May, the government's annual flu vaccination programme letter indicated that individuals aged 50 to 64 won't receive free flu vaccinations in the 2023/24 season. Moreover, the NHS plans to delay flu vaccine distribution to October, with the goal of enhancing protection for those aged 65 and older and other eligible groups during the winter months.

Deviating from the initial schedule to kick off the flu and Covid-19 vaccination campaigns in October, the NHS England has announced that the autumn vaccination drive will commence sooner than expected in England, starting on September 11. This decision was taken as a precaution in response to a new Covid-19 variant. The precautionary measure is being taken as the Department of Health and Social Care and the UK Health Security Agency examined the variant BA.2.86, which was first detected in the UK on Friday, August 18, 2023, the NHSE said on Aug. 30. While NHS England had previously announced that vaccinations for both NHS programmes would begin on October 2 for residents of older adult care homes, appointments for other eligible groups were scheduled for the following week, starting on October 7. This decision prompted community pharmacy leaders to denounce the delayed start of the flu service as 'unacceptable'.

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS). The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI) in April. Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's judgment. "While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the industry from the surge in the branded medicine payment rates. "The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in line with comparator countries to unlock investment and growth."

In the parliamentary drop-in-event hosted by Community Pharmacy England last week, Members of Parliament (MPs) questioned the Health Secretary on the rising issue of medicines supply. "Eighteen community pharmacists in my constituency are reporting challenges on medicine supplies. What more is the Minister going to do to get a grip of this situation?", Mike Amesbury MP for Weaver Vale, who was present at the event last week, asked the Health Secretary. In his response, the Health Secretary, Steve Barclay MP said: "We have a long-standing team in the Department focused on medical supplies, which are a continual issue; as a matter of routine business, there are often challenges in that area." The Shadow Pharmacy Minister, Karin Smyth MP, also asked: "People across the country rely on local, accessible pharmacies, but whether it is high street closures or supply problems leading to the absurd situation where women are phoning or visiting multiple pharmacies for a prescribed dose of hormone replacement therapy and other drugs…They have repeatedly announced plans to expand the role of community pharmacies but have failed to update legislation that could possibly help. … Why will they not do so?

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on the reclassification of codeine linctus to a prescription-only medicine after considering multiple Yellow Card reports for its opioid effects, rather than for its intended use as a cough suppressant. This medication is currently licensed as a pharmacy medicine, which means that it is available to purchase over the counter in pharmacies. If reclassified as a prescription-only medicine, all strengths of codeine linctus will only be available upon presentation of a prescription. Dr Alison Cave, MHRA Chief Safety Officer, said: "Codeine linctus is an effective medicine, but as it is an opioid, its misuse and abuse can have major health consequences. Every response received will help us to develop a broader view on whether codeine linctus should be restricted to prescription-only status. We want to hear from members of the public, health professionals and others who would be affected by this potential change so we can make a properly considered decision for the benefit of patients, carers, and healthcare professionals across the UK.

Community Pharmacy England has submitted a full and detailed written response to the Health and Social Care Select Committee's pharmacy inquiry. The Committee is expected to hold oral evidence sessions when Parliament returns in the Autumn. The commencement of this inquiry follows on from those held on other primary care sectors, including Dentistry and General Practice. According to the Committee website this inquiry 'will explore issues impacting different types of pharmacy, with a particular focus on community, primary care and hospital pharmacy services'. Key themes of CPE's submission include- Suggestions on future service provision; Challenges with the pharmacy workforce; Longstanding underfunding of the sector; and Current pressures. Janet Morrison OBE, Chief Executive of Community Pharmacy England, said: "This is an extremely important opportunity for all who work with and in the Pharmacy sector, to highlight not only the extreme challenges we face, but also ideas and suggestions for what more we can do to help patients and the public in the future.

Following Community Pharmacy England's Parliamentary drop-in event on medicines supply issues last week, several MPs have since raised questions to the Health Secretary during a Health Questions session on July 18th. According to CPE, MPs from all Parties displayed great engagement with the current pressures facing community pharmacies, particularly regarding medicines supply issues. During last week's event, Mike Amesbury, the MP for Weaver Vale, was present and directed a question to the Health Secretary: "Eighteen community pharmacists in my constituency are reporting challenges with medicine supplies. What further actions will the Minister take to address and resolve this situation effectively?" In response, Health Secretary Steve Barclay MP stated, "We have a dedicated team in the Department that focuses on medical supplies, which are an ongoing concern. Challenges in this area are a routine part of our business."

The National Pharmacy Association (NPA) has emphasised that the community pharmacy sector must be involved right from the start in all local planning meetings pertaining to the roll-out of vaccine services in potential future pandemics. This includes crucial discussions regarding supply logistics and resource allocation, lawyers representing the NPA told COVID-19 public inquiry hearing. Chaired by Baroness Heather Hallett, the independent public inquiry is examining the UK's response to the Covid-19 pandemic and lessons for the future. The NPA has been designated as a 'core participant' in Module 4 (vaccines) of the inquiry, which considers various issues related to vaccine development and rollout, as well as Module 3 (healthcare). During the hearing on September 13, NPA lawyers outlined three key areas the association says must be improved in future pandemic vaccination programs, including properly utilising existing primary care expertise, better planning and engagement, and improved access to information for community pharmacists.

Preet Kaur Gill, Shadow Minister for Primary Care and Public Health, has paid a recent visit to a community pharmacy in Staffordshire to personally experience the services it provides to patients, while staying updated on the latest sector developments. Her visit to Eason's Pharmacy in Tamworth on September 22nd marked her first since assuming new responsibilities for pharmacy policy matters within Labour's health team. Gill was also joined by a member of the National Pharmacy Association staff. The Minister received a comprehensive briefing on Eason's Pharmacy from its third-generation owner, Kieran Eason (R). He outlined the NHS services, which include the New Medicines Service and blood pressure monitoring, and showcased two consultation rooms and an operational dispensary. "It's great that Preet came to learn firsthand about the challenges we face and the substantial potential of community pharmacies nationwide," Eason said. "As an independent prescriber, I have the expertise to provide even more convenient care, but the current funding levels severely limit our contribution."

Pharmacists on the temporary register will be automatically removed on April 1, unless they have applied to rejoin the permanent register, the General Pharmaceutical Council has said. The government asked the GPhC and other pertinent health professional regulators to close temporary registers by March 31, 2024. According to the GPhC, this decision is based on the anticipation that the emergency conditions justifying the establishment of these temporary registers will cease after the approaching winter. The temporary register was established after the Health and Social Care Secretary asked the Council to utilise its emergency powers to swiftly register pharmacy professionals for their essential role in the national COVID-19 response. Pharmacists and pharmacy technicians who had previously opted to withdraw from the GPhC register or failed to renew their registration are now eligible for immediate re-registration, the regulator added.

Pharmacist Support, a charity centred on bolstering pharmacist well-being, has launched the 'ACTNow' campaign 2023, aimed at promoting and supporting the health and overall wellbeing of pharmacists. This campaign is launched following the successful 2022 initiative, which heightened awareness about wellbeing in the pharmacy profession. Launched in May 2020 in response to COVID-19 challenges, ACTNow has transformed into a dynamic platform fostering positive workplace culture, teamwork, and individual well-being, Pharmacist Support has said. Its primary goals are to inspire individuals and teams in the profession to prioritise their well-being, support colleagues, and proactively foster a healthier work environment. Pharmacist Support emphasised that the 2023 ACTNow campaign will continue to prioritise fostering a positive workplace culture. "This year, the campaign will provide individuals, pharmacy teams, and employers with essential tools, resources, and strategies to effectively support colleagues dealing with distress, all while cultivating a growth-oriented mindset within their teams," the charity firm said.

Boots UK is set to start recruiting for a new superintendent pharmacist as Marc Donovan moved into a new role. The company announced the appointment of Anne Higgins as the new pharmacy director for Boots UK. A Boots veteran for 25 years, she has been in the role of director for stores for more than two years since starting her journey as a pre-register pharmacist in July 1997. Marc Donovan will be moving into the new role of director of healthcare development and public affairs for Boots. Earlier this year Donovan was appointed the Order of the British Empire (OBE) "for services to pharmacy" in the Queen's Birthday Honours list. Donovan and Higgins will be reporting to Jamie Kerruish, the director of healthcare at Boots UK. A Boots spokesperson told Pharmacy Business: "We will be recruiting for a new superintendent pharmacist and once this appointment is made, Marc will hand over his superintendent responsibilities"

The Pharmacists' Defence Association (PDA) has submitted a 17-page contribution to the commission on the future of pharmacy professional leadership and encourages pharmacists to engage in the overall discussion. The association wants to ensure that the voice of its members is heard in the discussions about the future of professional leadership, which has been initiated by the four government Chief Pharmaceutical Officers. The PDA has published its first formal contribution to the commission, in its response it raised concern on the current exercise is being rushed and a call for the review to be conducted in a more sensible timeframe, one which enables the engagement of the whole profession. It has urged on being supportive of the creation of a Royal College of Pharmacists to take custodianship of the training and education for pharmacists and to set the requisite standards, whilst still relying upon the profession's regulators to undertake the accreditation role.

More than half of people (52%) do not feel confident in treating backache and less than half (44%) uses community pharmacists' advice as their first step on self-treatable conditions, a self-care attitudes 2022 survey has revealed. PAGB, the consumer healthcare association, surveyed over 2,000 adults across the UK about their attitudes towards self-care and access to health services. According to the survey, the public is in favour of self-care but many people lack the confidence and knowledge to care for the most common self-treatable conditions including backaches, headaches, diarrhoea and constipation. Four in five respondents (79%) said that people should take more responsibility for their own health and three-quarters (73%) believe that the NHS should make self-treatment easier. Behaviours around the current use of pharmacy varied - with less than half (44%) using community pharmacists as their first step in in getting advice on self-treatable conditions - but longer term attitudes were encouraging, with 69% supporting the idea of GPs being able to make referrals to pharmacists. Respondents also supported expanding the role of pharmacists so that their skills can be better utilised.

The UK's Health Security Agency (UKHSA) said mistakes at a testing laboratory led to misreporting of tens of thousands of positive COVID-19 cases as negative and may have resulted in the deaths of about 20 people. Britain has one of the highest coronavirus death tolls in the world, with more than 177,000 deaths since the pandemic started in 2020. Many experts have said the contact tracing programme fell well short of the "world-beating" system the government had promised. An investigation by the government agency responsible for responding to public health emergencies said the Immensa laboratory in central England was found to have misreported around 39,000 tests as negative when they should have been positive between September 2 and October 12 last year.